Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
MagGenix logo — Transforming Cell Therapeutics Through Magnetic Precision

MagGenix

Transforming Cell Therapeutics Through Magnetic Precision

Founded 2021 United States Baltimore, United States 7 employees Biopharma, Biotechnology +1

General Information

Company Name MagGenix
Founded Year 2021
Location United States Baltimore, United States
Employees 7
Industries Biopharma, Biotechnology, Health and Wellness
Social

BounceWatch is an independent company data service, not affiliated with MagGenix. To contact MagGenix, visit maggenix.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does MagGenix compare?

A PDF of MagGenix and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting MagGenix soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About MagGenix

MagGenix is a pioneering biotech startup aiming to revolutionize cell therapeutics through its innovative magnetogenetic cell therapy platform. By leveraging electromagnetic activation, MagGenix's technology offers precise and localized therapeutic stimulation with adjustable intensity, addressing critical challenges in healthcare, bioproduction, and research domains. The company's platform enables the activation of engineered cells in clinical, industrial, and research settings, marking a significant advancement in the field of biopharma and biotechnology. From a healthcare standpoint, the technology facilitates the targeted activation of cells, allowing for localized immunostimulation and immunosuppression without disrupting the body's entire immune system, using non-invasive electromagnetic stimulation. This opens doors for groundbreaking applications such as MagGenix-enabled CAR-T cells functioning exclusively at tumor sites and engineered regulatory T cells secreting antibodies solely at inflamed locations, offering potential therapeutic benefits in cancer and autoimmune diseases. In the realm of bioproduction, MagGenix's platform presents cost-efficient solutions for cellular activation and modulation in large-scale bioreactors, which could significantly impact industrial-scale synthesis processes and efficiencies. Moreover, within research, the company's platform has the potential to establish magnetogenetics as the preeminent method for perturbing and comprehending biological systems, supplanting conventional opto-/chemo-genetic approaches. Utilizing magnetic precision, MagGenix stands at the forefront of advancing cell therapies across patient care, scientific exploration, and large-scale bioproduction. Founded in 2021 and based in the United States, MagGenix presents an intriguing opportunity for potential investors within the biotech and healthcare sectors. With a novel technology poised to address unmet clinical needs and enhance bioproduction processes, MagGenix holds promise for disrupting and advancing multiple industries. As the company navigates its development and growth, upcoming updates on its website, Crunchbase, and AngelList will provide valuable insights into its progress and potential future investment opportunities.

Business keywords: Magnetogenetic Therapy, Cell Engineering, Bioproduction, Immunotherapy, Synthetic Biology, T-Cell Engineering, Bioreactor Modulation, Cancer Treatment, Immunosuppression, Research Technology, Bioengineering, Precision Medicine, Medical Innovation

No funding data available for MagGenix yet.

MagGenix Alternatives & Competitors

View All Alternatives
MagGenix vs
Strand Therapeutics
Strand Therapeutics United States

Where synthetic biology meets RNA therapeutics

Series A
121 employees
Biotechnology, Health and Wellness
MagGenix vs
Refuge Biotechnologies
Refuge Biotechnologies United States

DESIGNING INTELLIGENT CELL THERAPIES TO FIGHT CANCER

Series B
3 employees
Biotechnology, Health Care
MagGenix vs
Kernal Biologics
Kernal Biologics United States

KernalBio creates mRNA therapies that instruct specific cells on how to make their own medicine

Series A
22 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About MagGenix

Transforming Cell Therapeutics Through Magnetic Precision
MagGenix was founded in 2021.
MagGenix is headquartered in Baltimore, United States.
MagGenix operates in Biopharma, Biotechnology and Health and Wellness. Its work centres on Magnetogenetic Therapy, Cell Engineering, Bioproduction and Immunotherapy.
MagGenix has approximately 7 employees.
Top alternatives and competitors to MagGenix include Strand Therapeutics, Refuge Biotechnologies, Kernal Biologics, VaxCell Biotherapeutics Co., Ltd., Altheia Science. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MagGenix and Strand Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for MagGenix, https://bouncewatch.com/company/maggenix, updated 29 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes